Xenon

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Xenon
Accession Number
DB13453
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
3H3U766W84
CAS number
7440-63-3
Weight
Average: 131.293
Monoisotopic: 131.904154457
Chemical Formula
Xe
InChI Key
FHNFHKCVQCLJFQ-UHFFFAOYSA-N
InChI
InChI=1S/Xe
IUPAC Name
xenon
SMILES
[Xe]

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic AcidThe risk or severity of hypertension can be increased when 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid is combined with Xenon.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Xenon.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Xenon.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of hypertension can be increased when Xenon is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Xenon.
4-MethoxyamphetamineThe risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Xenon.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of hypertension can be increased when Xenon is combined with 5-methoxy-N,N-dimethyltryptamine.
AbediterolThe risk or severity of hypertension can be increased when Abediterol is combined with Xenon.
AcebutololXenon may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Xenon.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C13373
ChemSpider
22427
ChEBI
49957
ChEMBL
CHEMBL1236802
HET
XE
Wikipedia
Xenon
ATC Codes
N01AX15 — Xenon
PDB Entries
1c10 / 1c1m / 1c3l / 1c62 / 1c65 / 1c68 / 1c6b / 1c6e / 1c6h / 1c6k
show 127 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingOtherCystic Fibrosis (CF)1
0CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
0Not Yet RecruitingDiagnosticAsbestosis / Asthma / Bronchiectasis / Chronic Obstructive Pulmonary Disease (COPD) / Cold Virus / Cystic Fibrosis (CF) / Emphysema / Interstitial Lung Disease (ILD) / Lung Cancers / Lung Infection / Lung Resection / Lung Transplant / Mesothelioma / OSAS (Obstructive Sleep Apneas Syndrome) / Pulmonary Dysplasia / Pulmonary Embolism / Pulmonary Fibrosis / Pulmonary Hypertension (PH) / Seasonal Allergies1
0Not Yet RecruitingTreatmentDepression, Bipolar / Major Depressive Disorder (MDD)1
0RecruitingBasic ScienceAlzheimer's Disease (AD)1
1CompletedTreatmentSympathetic Nervous System1
1RecruitingBasic ScienceBMI >30 kg/m21
1RecruitingDiagnosticAlpha 1-Antitrypsin Deficiency / Asthma / Chronic Obstructive Pulmonary Disease (COPD) / Cystic Fibrosis (CF) / Interstitial Lung Disease (ILD) / NSIP / Pulmonary Hypertension (PH)1
1RecruitingDiagnosticChronic Lung Diseases1
1RecruitingDiagnosticIdiopathic Pulmonary Fibrosis (IPF)1
1RecruitingDiagnosticRadiation Injuries1
1, 2RecruitingDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
1, 2RecruitingDiagnosticRespiratory Disorders2
1, 2Unknown StatusTreatmentHypoxic Ischaemic Encephalopathy (HIE)1
2Active Not RecruitingTreatmentHypoxic Ischaemic Encephalopathy (HIE)1
2CompletedDiagnosticAsthma / Chronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
2CompletedSupportive CareColorectal Cancers1
2CompletedTreatmentAnaesthesia therapy / Coronary Artery Disease2
2CompletedTreatmentDelirium1
2CompletedTreatmentIschemic Brain Injury1
2Not Yet RecruitingDiagnosticIdiopathic Pulmonary Fibrosis (IPF)1
2RecruitingBasic ScienceNeurocognitive Dysfunction1
2RecruitingDiagnosticAsthma / Cystic Fibrosis (CF)1
2RecruitingDiagnosticLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentAddition to Therapeutical Hypothermia / Efficacy and Safety of Xenon Inhalation / Successful Cardiopulmonary Resuscitation1
2WithdrawnTreatmentObsessive Compulsive Disorder (OCD)1
2, 3CompletedTreatmentAsthma1
2, 3Not Yet RecruitingTreatmentPost Traumatic Stress Disorder (PTSD)1
3CompletedScreeningCoronary Arteries Disease Risk / Elevated Cardiac Risk1
3CompletedTreatmentAnaesthesia / Postoperative Cognitive Functions1
3CompletedTreatmentAnesthetics, Inhalation / Coronary Artery Bypass Graft Surgery Patients / Coronary Heart Disease (CHD) / Sevoflurane / Xenon1
3CompletedTreatmentCoronary Artery Bypass Graft Surgery Patients / Coronary Artery Disease / General Anesthetic Drug Allergy1
3CompletedTreatmentRenal Function After Partial Nephrectomy1
3RecruitingOtherLung Structure Determination1
3RecruitingTreatmentPost-Cardiac Arrest Syndrome1
3TerminatedBasic ScienceHealthy Volunteers1
3TerminatedTreatmentAnaesthesia1
4CompletedOtherAnaesthesia therapy1
4CompletedTreatmentAnaesthetics Gases, Xenon / Anaesthetics Volatile, Sevoflurane / Depth of Anaesthesia / Nausea, Postoperative / Vomiting Postoperative1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentHemodynamic Stability1
4WithdrawnTreatmentLiver Function After Partial Liver Resection1
Not AvailableActive Not RecruitingPreventionAortic Dissection1
Not AvailableCompletedNot AvailableAnaesthesia therapy1
Not AvailableCompletedNot AvailableEncephalopathies / Perinatal Asphyxia1
Not AvailableCompletedDiagnosticCerebrovascular Accident / Moyamoya Disease1
Not AvailableCompletedPreventionEndarterectomy, Carotid1
Not AvailableRecruitingNot AvailableCystic Fibrosis (CF)2
Not AvailableRecruitingTreatmentAcute Lung Injury (ALI)1
Not AvailableRecruitingTreatmentAsthma; Eosinophilic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as homogeneous noble gases. These are inorganic non-metallic compounds in which the largest atom is a halogen atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Homogeneous noble gases
Sub Class
Not Available
Direct Parent
Homogeneous noble gases
Alternative Parents
Not Available
Substituents
Homogeneous noble gas
Molecular Framework
Not Available
External Descriptors
monoatomic xenon (CHEBI:49956)

Drug created on June 23, 2017 14:42 / Updated on December 02, 2019 09:59